Filing Flows › Comparisons › IBIO vs ACUT
iBio vs Accustem Sciences: IBIO and ACUT compared
iBio is the larger company: $100K of revenue in its latest quarter (Q1 FY26) against $98K for Accustem Sciences (Q2 2026).
Where the money goes: IBIO and ACUT
iBio (IBIO) · Q1 FY26
iBio, Q1 FY26: revenue $100K, net loss $5.7M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
Accustem Sciences (ACUT) · Q2 2026
Accustem Sciences, Q2 2026: revenue $98K, operating margin -256.7%, net loss $253K, operating cash flow −$249K. The chart follows the revenue to costs, profit and cash.
| iBio (IBIO) | Accustem Sciences (ACUT) | |
|---|---|---|
| Latest quarter | Q1 FY26 | Q2 2026 |
| Revenue | $100K | $98K |
| Operating margin | n/m | -256.7% |
| Net earnings | −$5.7M | −$253K |
| Net margin | — | -256.7% |
| Operating cash flow | −$5.7M | −$249K |
Questions
Which is bigger, iBio or Accustem Sciences?
iBio is the larger company: $100K of revenue in its latest quarter (Q1 FY26) against $98K for Accustem Sciences (Q2 2026).
More: iBio earnings · how iBio makes money · Accustem Sciences earnings · how Accustem Sciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 12, 2025; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.